# B002 in Patients With HER2-positive Breast Cancer

> **NCT04382352** · PHASE1 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.

## Key facts

- **NCT ID:** NCT04382352
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-04-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382352, "B002 in Patients With HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04382352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*